Nivolumab and ipilimumab: drug combination has added benefit in advanced renal cell carcinoma

15 May 2019 - There are no serious disadvantages in terms of overall survival. ...

Read more →

Apalutamide in prostate cancer: indication of significant added benefit

2 May 2019 - Study shows significant slowing of symptomatic progression. ...

Read more →

Ribociclib in advanced breast cancer: survival benefits, but also severe side effects

15 April 2019 - In the overall view, an added benefit is not proven. ...

Read more →

Single-payer drug pricing in a multi-payer health system: does Germany offer a model for the US?

22 March 2019 - An increasing number of presidential hopefuls, most recently Senator Kamala Harris, are proposing “single payer” or “Medicare ...

Read more →

Numerous G-BA decisions on new medicines - five active substances with considerable added value

22 March 2019 - On Friday in Berlin, the Federal Joint Committee (G-BA) made numerous decisions on the extent of the ...

Read more →

Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany

5 March 2019 - The decision matrix applied by the IQWiG for the quantification of added benefit within the early benefit ...

Read more →

Germany agrees on new pharmaceutical bill

13 February 2019 - On 30 January, the German government has agreed on a draft Act for more safety in ...

Read more →

Erenumab in migraine: indication of a significant added benefit for certain patients

2 February 2019 - As a prophylaxis successful when other drug therapies are exhausted. ...

Read more →

Identifying the need for good practices in health technology assessment-summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA

26 January 2019 - The systematic use of evidence to inform healthcare decisions, particularly health technology assessment, has gained increased recognition.  ...

Read more →

Citizens ask - scientists answer: the IQWiG sets four new topics for HTA reports

23 January 2019 - Citizens, patients and medical experts: selection of topics with a sense of proportion ...

Read more →

Progressive squamous cell carcinoma of the head and neck: pembrolizumab prolongs survival

15 January 2019 - Only a few study participants were treated in compliance with the approval, therefore the extent of ...

Read more →

Rexgenero's lead product REX-001 selected for the EUnetHTA prioritisation list for joint assessments

7 January 2019 - The Prioritisation list consists of just 14 medicinal products that have been identified as being of significant ...

Read more →

EU Health Technology Assessment needs to move up a gear, says pressure group

9 January 2019 - The European Alliance for Personalised Medicine says it may seem to everyone that the whole debate ...

Read more →

Mandatory or voluntary? A sticking point for European HTA

10 January 2019 - The long road to unified European Health Technology Assessment is continuing.  ...

Read more →

2018 in a nutshell: new edition with facts and graphics from the IQWiG

9 January 2019 - The focus of the 33-page brochure is information, overviews and charts on "Health Technology Assessment (HTA) ...

Read more →